Pretomanid Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 200 mg
Reference Brands: Afiniti
Category:
Antibiotics
Pretomanid is available in Tablets
and strengths such as 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pretomanid is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pretomanid can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pretomanid is an antibiotic medication used in the treatment of multi-drug-resistant tuberculosis (MDR-TB) affecting the lungs. It is specifically indicated for use in adults as part of combination therapy with bedaquiline and linezolid for pulmonary extensively drug-resistant tuberculosis, or in patients who are treatment-intolerant or nonresponsive to standard MDR-TB regimens.
As a nitroimidazooxazine antimycobacterial agent, pretomanid works by inhibiting the synthesis of mycobacterial cell wall components and generating reactive nitrogen species that kill Mycobacterium tuberculosis. Its targeted mechanism makes it highly effective against drug-resistant strains of TB, which are difficult to treat with conventional antibiotics.
Pretomanid is administered orally as 200 mg tablets, allowing convenient integration into combination therapy regimens. When used alongside bedaquiline and linezolid, pretomanid has shown significant clinical efficacy in improving treatment outcomes in adults with highly resistant pulmonary tuberculosis.
This therapy represents an important advancement in global TB management, providing a viable option for patients with limited treatment choices and helping to combat the growing challenge of drug-resistant tuberculosis worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing